Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
about
Environmental risk factors for inflammatory bowel diseases: Evidence based literature reviewDiscontinuation of Scheduled Infliximab in Crohn's Patients With Clinical Remission: A Retrospective Single-Center Study.Care of inflammatory bowel disease patients in remission.The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Practical Approaches to "Top-Down" Therapies for Crohn's Disease.Characteristics and Behavior of Elderly-onset Inflammatory Bowel Disease: A Multi-center US Study.European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly.Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease.Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply.Association of Coloproctology of Great Britain and Ireland consensus exercise on surgical management of fistulating perianal Crohn's disease.Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland.Highlights From the New ACG Guideline on Crohn's Disease ManagementCost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
P2860
Q30248747-B6E4C93F-CA4E-45DE-8881-19D3A1A161D3Q33625252-14CBAA53-6EDD-460F-B82B-E72042ABF1E0Q37540172-CA6AFB8B-E81B-40E7-8FF8-3957C92B9AECQ38784697-808AAF0C-50F4-443E-9963-B437C6C2AB73Q38822920-4EF562B7-23C8-4E09-89E2-2E47055B53BFQ38835478-72965C95-261E-4458-BD8B-E9AB089C3639Q38916039-6180B3A1-ED94-44B2-A792-E2337736EDFAQ38995105-9A1D2130-6FFD-4EE3-BE25-73FF3AC03B45Q39353122-8CFC2CE7-4D9E-4C53-B29F-EB4397D743F3Q39612269-A1DB4F75-84BB-42B8-A81F-0F13B7D0C14FQ41990807-4EF3D792-DDAA-46A2-AF22-00B4EE583529Q48139155-618B1116-78E3-462D-BC3E-94CC61A7E38DQ48306632-795455AB-614F-47C4-95C5-0A0165AAB246Q48904882-561CFC4D-3BED-48C7-AC41-6684AA92BD8FQ52581473-A57598A8-7253-4A0C-8F65-BA4D536397EAQ55363187-B623230B-2100-4816-81D9-AB191C3D4E62Q57301025-DEF867A0-6B41-4009-9F70-5D1B4D806A0EQ58803120-E4FDD95F-DB37-454F-A441-D6C7BCACD170
P2860
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Systematic review: factors ass ...... tinuation of anti-TNF therapy.
@en
type
label
Systematic review: factors ass ...... tinuation of anti-TNF therapy.
@en
prefLabel
Systematic review: factors ass ...... tinuation of anti-TNF therapy.
@en
P2860
P50
P356
P1476
Systematic review: factors ass ...... ntinuation of anti-TNF therapy
@en
P2093
P2860
P304
P356
10.1111/APT.13276
P407
P577
2015-06-15T00:00:00Z